FDA approves 1st drug to treat postpartum depression
Postpartum depression affects as many as 400,000 women in the United States every year, and on Tuesday, the Food and Drug Administration approved the first drug specifically created to treat the disorder.
Brexanolone, also known as Zulresso, is delivered intravenously. The infusion takes 60 hours, and during a clinical trial, most participants showed improvement within 24 hours of receiving the drug, reporting they still felt the effects 30 days later. Brexanolone contains a synthetic form of allopregnanolone, a derivative of progesterone, which increases during pregnancy and drops dramatically after giving birth. It is thought allopregnanolone could contribute to postpartum depression.
Women with postpartum depression often feel profound sadness, anxiety, or despair. Many are treated with antidepressants that take weeks to kick in or sometimes don't work at all, as they do not address the hormonal changes that happen during and after pregnancy. Each Zulresso infusion is expected to cost $20,000 to $35,000, NBC News reports, and it's unknown how much insurance will cover. Researchers said each patient will likely only need one infusion. It is expected the FDA will soon decide if the drug is safe for women to use while breastfeeding.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
How does the House Ethics Committee work?
In the Spotlight And what does that mean for Matt Gaetz?
By Joel Mathis, The Week US Published
-
The ultimate podcast list of 2024
The Week Recommends Some of the best podcast series released in the past year or so
By The Week UK Published
-
Crossword: December 26, 2024
The Week's daily crossword
By The Week Staff Published
-
Honda and Nissan in merger talks
Speed Read The companies are currently Japan's second and third-biggest automakers, respectively
By Peter Weber, The Week US Published
-
Taylor Swift wraps up record-shattering Eras tour
Speed Read The pop star finally ended her long-running tour in Vancouver, Canada
By Peter Weber, The Week US Published
-
Drake claims illegal boosting, defamation
Speed Read The rapper accused Universal Music of boosting Kendrick Lamar's diss track and said UMG allowed him to be falsely accused of pedophilia
By Rafi Schwartz, The Week US Published
-
'Wicked' and 'Gladiator II' ignite holiday box office
Speed Read The combination of the two movies revitalized a struggling box office
By Peter Weber, The Week US Published
-
Jussie Smollet conviction overturned on appeal
Speed Read The Illinois Supreme Court overturned the actor's conviction on charges of staging a racist and homophobic attack against himself in 2019
By Peter Weber, The Week US Published
-
Airplane food is reportedly getting much worse
Under the radar Cockroaches and E. coli are among the recent problems encountered in the skies
By Justin Klawans, The Week US Published
-
Quincy Jones, music icon, is dead at 91
Speed Read The legendary producer is perhaps best known as the architect behind Michael Jackson's 'Thriller'
By Peter Weber, The Week US Published
-
OJ Simpson, star athlete tried for murder, dead at 76
Speed Read The former football hero and murder suspect lost his battle with cancer
By Rafi Schwartz, The Week US Published